ArticleJTO clinical and research reports2023

Efficacy and Safety of Anti-Programmed Death-Ligand 1 Monoclonal Antibody Socazolimab With Carboplatin and Etoposide for Extensive-Stage SCLC: Results From the Phase 1b Clinical Trial.

Shun Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.